🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
NCT07227207Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics, Inc.
Phase 1/2
72
London, Nottingham
2026-04-21
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182Juvenile Idiopathic Arthritis (JIA)
Alfasigma S.p.A.
Phase 3
80
London
2026-04-20
By invitation
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT07573631Duchenne Muscular Dystrophy (DMD)
BioMarin Pharmaceutical
Phase 2
18
London
2026-04-20
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
BioMarin Pharmaceutical
Phase 2/3
160
Bristol, Glasgow, Liverpool, London, Manchester
2026-04-20
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Coventry, Liverpool, London, Westcliff-on-Sea
2026-04-16
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Khondrion BV
Phase 3
220
London
2026-04-14
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Edinburgh, London
2026-03-31
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746Primary Membranous Nephropathy
AstraZeneca
Phase 2
43
London, Manchester
2026-03-28
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Leicester, Liverpool, London
2026-03-27
Recruiting
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
NCT07352423Healthy Adult Participants
Alexion Pharmaceuticals, Inc.
Phase 1
48
London
2026-03-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941Alzheimer Disease, Psychosis
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
A Long-Term Observational Study of Patients With Fucosidosis
NCT07615400Fucosidosis
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
Kiniksa Pharmaceuticals International, plc
Phase 2
80
London
2026-03-25
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
NCT07235592Primary Open Angle Glaucoma
Santen SAS
Observational
112
London
2026-03-19
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Recruiting
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
NCT07446855Solid Tumours
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
NCT07431112Alpha 1 Antitrypsin Deficiency
AIRNA Corporation
Phase 1
54
Cambridge, London, Southampton
2026-03-17
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
London, Glasgow, Metropolitan Borough of Wirral
2026-03-16
Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
NCT07457580Type 1 Diabetes
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
Astellas Pharma Global Development, Inc.
Phase 2
240
London
2026-03-12
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
NCT07347249Congenital Factor VII Deficiency
Hemab ApS
Phase 2
18
London
2026-03-11
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, London, Manchester
2026-03-09
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT07427680Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc
Phase 1/2
99
London
2026-03-03
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.
Phase 3
540
Cambridge, Glasgow, London, Sheffield, Swindon
2026-03-03
Recruiting
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
NCT07535606Healthy Volunteers
Alnylam Pharmaceuticals
Phase 1
44
London
2026-03-02
Not yet open
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction
NCT07403058Heart Failure With Reduced Ejection Fraction (HFrEF)
Axon Therapies, Inc.
Not applicable
50
Leeds, London
2026-03-01
Active, closed
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
NCT07718139Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Observational
300
London
2026-02-28
Recruiting
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
NCT07454837Chronic Hepatitis D
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Cottingham, Cardiff, London, Manchester
2026-02-26
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.
Phase 2
100
London
2026-02-18
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
614
Cambridge, Cottingham, Ipswich, London, Maidstone, Sutton
2026-02-17
Recruiting
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333Schizophrenia
Neurocrine Biosciences
Phase 2
120
London, Oxford
2026-02-16
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
Merck Sharp & Dohme LLC
Phase 3
900
Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Leicester, London, Salford
2026-02-16
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
NCT07187401Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
Regeneron Pharmaceuticals
Phase 1/2
24
Leeds, London
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
80
Exeter, London
2026-02-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
AstraZeneca
Phase 2
124
Brighton, Guildford, Liverpool, London
2026-02-10
Recruiting
A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older
NCT07421713Osteoporosis, Osteopenia
Promedius Inc
Observational
595
Westcliff-on-Sea, London
2026-02-10
Not yet open
The Concert Therapy for Stress Regulation in a Non-Clinical Adult Population
NCT07430631Stress Regulation and Well-being in Non-clinical Contexts
Behnam Khodarahmi
Not applicable
150
London
2026-02-09
Recruiting
RIG 101 Trial in Healthy Adults and Adults With Asthma
NCT07488897Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
RIGImmune Inc.
Phase 1/2
82
London, Manchester
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
NCT07232602Bladder Cancer
Merck Sharp & Dohme LLC
Phase 1/2
55
London
2026-02-09
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
NCT07358156Atopic Dermatitis
Chong Kun Dang Pharmaceutical
Phase 1
519
London
2026-02-09
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Cambridge, Dundee, Leeds, London, Manchester, Oxford
2026-02-03
Recruiting
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
NCT07155850Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable
BetaGlue Therapeutics SpA
Not applicable
10
London
2026-02-03
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
Alnylam Pharmaceuticals
Phase 3
125
London
2026-02-03
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360Sickle Cell Disease
CSL Behring
Phase 2
63
London
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
Prilenia
Phase 3
500
London, Stoke-on-Trent
2026-02-01
Recruiting
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
NCT07080385Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
London, Manchester
2026-01-30
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451Alzheimer Disease, Early Onset
Denali Therapeutics Inc.
Phase 1
68
London
2026-01-30
Recruiting
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654Eosinophilic Asthma
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Active, closed
Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes
NCT07039357Diabetes Mellitus, Healthy
Glyconics Ltd
Not applicable
100
Ashton-under-Lyne, London
2026-01-28
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942Alzheimer's Disease
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
IDEAYA Biosciences
Phase 3
520
Metropolitan Borough of Wirral, London, Sheffield
2026-01-25
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
NCT07430397Factor V Leiden, Prothrombin G20210A
City Therapeutics
Phase 1
128
London
2026-01-22
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Liverpool, London, Manchester, Sheffield
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846Severe Asthma
Generate Biomedicines
Phase 3
786
High Wycombe, Ashburton, Bristol, London, Romford, Rotherham, Thetford, Nottingham
2026-01-20
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800Lupus Nephritis
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
Phase 1/2
181
London
2026-01-13
Active, closed
Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions
NCT07410143Pediatric SDLT CNS Disorders
EveryONE Medicines Inc.
Phase 1/2
1
London
2026-01-13
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
Kailera
Phase 3
1,156
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
Recruiting
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261Fabry Disease
Amicus Therapeutics
Phase 3
8
London, Manchester
2026-01-08
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459Idiopathic Pulmonary Fibrosis
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Glasgow, Southampton
2026-01-07
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Liverpool, London, Southampton
2026-01-07
Rows per page Showing 101–200 of 2005
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=2

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.